BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the company has entered into a privately-negotiated securities exchange agreement with a holder of BioSante’s 3.125% convertible senior notes ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced a corporate update. Corporate development: In light of the recently announced ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced top-line results from its two pivotal Phase III LibiGel (testosterone gel) efficacy trials. Initial analysis of the data from these trials ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the issuance of a new U.S. patent covering the “method of use” of LibiGel (testosterone gel) for treating female sexual dysfunction ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has been added to the NASDAQ Biotechnology Index® (Symbol: NBI), effective prior to the stock market open today, November ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Top line data from this study were announced ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company’s pipeline. ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSante’s president & CEO will present at two healthcare conferences in October. Mr. Simes will speak at ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company’s anticipated LibiGel new drug application (NDA). The ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel ... read more

BioSante Pharmaceuticals, Inc. of Lincolnshire, IL has been honored with a recognition by R&D Directions in its selection of "100 Great Investigational Drugs." LINCOLNSHIRE, Ill., Aug. 31, 2011 /PRNewswire-USNewswire/ -- Announcing a special recognition appearing in the March, 2011 issue of R&D Directions published by Engel Publishing Partners. BioSante Pharmaceuticals, ... read more